

June 9, 2010

Dear Health Care Professional:

APP Pharmaceuticals recognizes how vital it is for clinicians and patients to receive a consistent supply of propofol. Because of a commitment to our customers, APP acted decisively to increase supply at the onset of this critical market shortage.

During this time, we have:

- Increased production of APP Diprivan®
- Initiated and increased production of APP authorized generic propofol
- Supplemented supply by importing international Fresenius Propoven 1% (propofol 1%), in agreement with the FDA.

With the announcement that Teva Pharmaceuticals would be discontinuing their line of propofol products and Hospira expanding their drug recall APP continues to be the only supplier of propofol.

APP is owned by Fresenius Kabi, the largest manufacturer of propofol injection in the world. The combined efforts of APP and Fresenius Kabi have focused on increasing propofol supply by bringing new capacity on line and as a result APP is currently producing at levels to supply the entire U.S. market.

At a significant incremental cost, APP is using air-freight to accelerate overseas deliveries from multiple European manufacturing facilities into the United States to ensure hospitals and clinics receive continual access to product. APP will continue these efforts until propofol supplies stabilize.

#### **Ordering Process:**

Allocation limits and procedures have been implemented that will help ensure all healthcare professionals receive this critical product. APP will make reasonable attempts to fill your orders. Customers have the following options when ordering APP's propofol, DIPRIVAN®, and/or Fresenius Propoven 1% (propofol 1%):

- Wholesalers can place drop ship orders on a customer's behalf directly with APP
- Customers who have previously ordered direct from APP can place their order by contacting Customer Service at 1-888-386-1300, between 7 a.m. – 6 p.m. (Central Daylight Saving Time)
- All other customers can establish a new direct account by completing APP's credit application at [www.APPpharma.com](http://www.APPpharma.com)

For clinical or technical questions regarding our products, please call APP's Medical Affairs Department at 1-800-551-7176 between the hours of 8 a.m. – 5 p.m. (Central Daylight Saving Time). For additional details regarding propofol, please visit [www.APPpharma.com](http://www.APPpharma.com).

Sincerely,



Deena Reyes  
Vice President  
Anesthesia/Analgesia